Qiagen NV (NYSE:QGEN) has received an average rating of “Hold” from the twenty analysts that are currently covering the firm, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $33.50.
Several research analysts have recently commented on QGEN shares. Evercore ISI raised Qiagen from an “in-line” rating to an “outperform” rating in a report on Thursday, November 14th. Berenberg Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Tuesday, October 1st. Zacks Investment Research upgraded Qiagen from a “sell” rating to a “hold” rating and set a $32.00 price objective for the company in a research report on Monday, November 4th. UBS Group reissued a “neutral” rating on shares of Qiagen in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. upgraded Qiagen from an “underweight” rating to an “overweight” rating and increased their target price for the stock from $25.00 to $40.00 in a report on Thursday, November 14th.
Shares of QGEN stock opened at $43.10 on Friday. The stock’s fifty day simple moving average is $34.00 and its 200 day simple moving average is $35.98. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.45 and a quick ratio of 2.18. The firm has a market cap of $9.65 billion, a price-to-earnings ratio of 32.16, a P/E/G ratio of 3.20 and a beta of 0.97. Qiagen has a one year low of $25.04 and a one year high of $43.16.
Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.01. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The firm had revenue of $382.70 million during the quarter, compared to analyst estimates of $382.98 million. During the same period in the prior year, the company posted $0.35 earnings per share. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. On average, research analysts anticipate that Qiagen will post 1.4 earnings per share for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of QGEN. Private Capital Group LLC increased its stake in shares of Qiagen by 354.0% in the 2nd quarter. Private Capital Group LLC now owns 681 shares of the company’s stock valued at $25,000 after acquiring an additional 531 shares during the last quarter. Quest Capital Management Inc. ADV acquired a new stake in shares of Qiagen in the 3rd quarter valued at approximately $37,000. Huntington National Bank raised its position in shares of Qiagen by 33.3% in the 3rd quarter. Huntington National Bank now owns 1,568 shares of the company’s stock valued at $52,000 after acquiring an additional 392 shares during the period. Tower Research Capital LLC TRC boosted its stake in Qiagen by 1,244.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,385 shares of the company’s stock worth $56,000 after acquiring an additional 1,282 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in Qiagen by 5,918.5% during the 2nd quarter. Bessemer Group Inc. now owns 1,625 shares of the company’s stock worth $66,000 after acquiring an additional 1,598 shares during the last quarter. Hedge funds and other institutional investors own 62.69% of the company’s stock.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.